COVID-19 therapeutic (Regeneron) procurement: ~$5.57B — the Army's order for up to 1.25M doses, a Warp Speed therapeutic (USAspending)

Whereas the Moderna contract covered separately on this site was a COVID-19 "vaccine (prevention)," this contract is Regeneron's "therapeutic (treatment)." If a vaccine is on the side of preventing infection, a therapeutic is on the side of treating patients already infected.

Regeneron's COVID-19 therapeutic is widely known as a monoclonal antibody medicine — turning the "antibodies" that capture foreign substances in the body into a drug. The description explicitly states the purchase of up to 1.25 million doses of the Emergency Use Authorization (EUA) therapeutic.

This contract too, like the Moderna vaccine procurement, was handled by the Department of Defense (the U.S. Army's procurement organization) as part of the cross-government "Operation Warp Speed." The same contracting machinery that buys weapons worked, during the pandemic, to secure at national scale both the "prevention" of vaccines and the "treatment" of therapeutics — placing Moderna (prevention) alongside this entry (treatment) reveals how the DoD procurement network supported the whole public-health crisis response.

The description (USAspending) goes as far as "up to 1.25M doses of the EUA therapeutic" and does not detail clinical specifics beyond that (this site does not fill in what the description omits). A cumulative ~$5.57B shows that vast sums were also poured into securing therapeutics in the pandemic response, and that the defense procurement apparatus was used for it.